<DOC>
	<DOC>NCT01627990</DOC>
	<brief_summary>The purpose of this study is to observe the tolerability, safety and efficacy of preventative treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.</brief_summary>
	<brief_title>Nivestim™ in Treatment of Malignant Diseases</brief_title>
	<detailed_description>This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with in-patients adults or minors undergoing cytotoxic chemotherapy, being treated prophylactically with Nivestim™ in order to reduce the duration of neutropenia and to reduce the incidence of chemotherapy-induced Febrile neutropenia (FN).</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>No age limit Declaration of informed consent signed by patient or legal guardian Patients with a solid tumour or with a malignant haematological tumour Patients for whom cytotoxic chemotherapy is planned, irrespective of cycle Patients who are due to undergo, or who should undergo, (primary or secondary) prophylactic treatment using Nivestim™, either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy induced febrile neutropenia (FN). Patients with chronic myeloid leukaemia (CML) or with myelodysplastic Syndrome (MDS) Patients who are hypersensitive to the active substance or to one of the excipients of Nivestim™ Patients not undergoing chemotherapy Patients being treated curatively with GranulocyteColony Stimulating Factor (GCSF)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>cytotoxic chemotherapy</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>Malignant haematological tumour</keyword>
</DOC>